EGFR‐TKI therapy has been associated with changes in the tumor immune microenvironment of EGFR‐mutated NSCLC, which may provide clues for further optimization of PD‐1 inhibitor therapy [31]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.